Zanubrutinib (Brukinsa)
An oral, next-generation BTK inhibitor used across several B-cell blood cancers, including CLL, lymphomas, and Waldenstrom macroglobulinemia.
What is Zanubrutinib?
What it targets
Bruton tyrosine kinase (BTK), a signalling protein in the B-cell receptor pathway that malignant B cells use to grow, survive, and persist in lymph nodes and bone marrow.
Who it may help
Adults with confirmed B-cell malignancies such as CLL/SLL, mantle cell lymphoma, Waldenstrom macroglobulinemia, marginal zone lymphoma, or relapsed follicular lymphoma, depending on local approval.
Why testing matters
The B-cell cancer must be confirmed by biopsy, flow cytometry, and marrow studies. Cardiac, bleeding, and infection risk are checked first because of known BTK-inhibitor side effects.
Which cancers can Zanubrutinib treat?
Zanubrutinib is approved or used across several B-cell malignancies. Approved uses and treatment lines vary by country, so eligibility must be confirmed locally.
| Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) | Approved for adults with CLL/SLL in the USA, Europe, China, and other regions, in both first-line and previously treated settings. Supported by the SEQUOIA and ALPINE trials, the latter a head-to-head study against ibrutinib. |
| Waldenstrom macroglobulinemia (WM) | Approved for adults with WM, including first-line use in some regions such as China. Supported by the ASPEN trial, a head-to-head comparison with ibrutinib. |
| Mantle cell lymphoma (MCL) | Approved in relapsed or refractory MCL after at least one prior therapy in several regions. This is an accelerated approval in the USA, based on response rate. |
| Marginal zone lymphoma (MZL) | Approved in relapsed or refractory MZL after at least one anti-CD20-based regimen in some regions, supported by the MAGNOLIA trial. Accelerated approval in the USA. |
| Follicular lymphoma (FL) | Approved in combination with obinutuzumab for relapsed or refractory FL after two or more prior systemic therapies in some regions, based on the ROSEWOOD trial. Accelerated approval in the USA. |
Are you eligible for Zanubrutinib?
Eligibility depends on a confirmed B-cell cancer diagnosis, the treatment setting, organ function, and bleeding, heart, and infection risk.
- A confirmed B-cell malignancy where BTK inhibition is appropriate, such as CLL/SLL, MCL, WM, MZL, or relapsed follicular lymphoma
- A treatment setting that is approved in your country, whether first-line or relapsed/refractory depending on the cancer type
- Disease that needs treatment based on symptoms, blood counts, bulky nodes, progression, or organ involvement
- Adequate blood counts and bone marrow reserve for ongoing therapy
- Adequate liver and kidney function for the chosen regimen
- No uncontrolled bleeding disorder or unstable heart rhythm problem that would make treatment unsafe
- No severe active infection at the time of starting, and a plan to manage infection risk
- No major drug interaction that cannot be managed by dose adjustment or substitution
How does Zanubrutinib work?
- Targeting the BTK signal
- Reducing survival signals
- Designed for selectivity
- Used alone or in combination
Zanubrutinib is a China-developed, next-generation BTK inhibitor and is the only one of its class to offer the flexibility of once-daily or twice-daily dosing.
Tests required before starting Zanubrutinib
These tests confirm the diagnosis, establish baselines, and check for risks specific to BTK inhibitors such as bleeding, infection, and heart rhythm problems.
| Biopsy and pathology review with immunophenotyping | Confirms the specific B-cell malignancy through tissue or marrow biopsy, flow cytometry, and immunohistochemistry. |
| Complete blood count (CBC) with differential | Baseline red cell, white cell, and platelet counts, monitored throughout treatment because cytopenias are common. |
| Liver and kidney function tests | Assess organ function and guide safety, since zanubrutinib is processed mainly through the liver. |
| Hepatitis B, hepatitis C, and infection screening | Checks for infections that may need treatment or monitoring before starting an immune-affecting therapy. |
| Cardiac review or ECG when indicated | Recommended if there is a history of atrial fibrillation, palpitations, heart disease, or high blood pressure. |
| Bleeding risk and medication review | Reviews blood thinners, aspirin, anti-inflammatories, and any planned surgery, because zanubrutinib can increase bleeding. |
| FISH, karyotyping, or NGS, and disease-specific markers | Defines risk features such as del(17p) or TP53 in CLL, and MYD88 or CXCR4 in Waldenstrom macroglobulinemia, where useful. |
How is Zanubrutinib given?
Zanubrutinib is taken by mouth at home. The exact dose, formulation, and schedule are set by the treating doctor and the local prescribing information.
| Total daily dose | The recommended total dose is 320 mg per day, which can be taken as 320 mg once daily or as 160 mg twice daily. |
| Formulation — tablet | A 160 mg film-coated tablet, so the 320 mg dose is usually two tablets daily. The tablet replaced the older capsule in the USA from October 2025. |
| Formulation — capsule | The original 80 mg capsule, where four capsules made up the 320 mg dose. Availability of capsule versus tablet depends on the country. |
| How to take | Swallowed whole with water, with or without food. Do not break, chew, or open the tablets or capsules. |
| Missed dose | If a dose is missed, take it as soon as you remember on the same day, then return to the normal schedule. Do not double up. Ask your team for specific advice. |
| Duration | Usually continued long term, until the disease progresses or side effects become unacceptable. Some combination regimens run for a set period. |
Clinical evidence and benefits
Zanubrutinib has been studied in large trials across several B-cell cancers, including head-to-head comparisons with the older BTK inhibitor ibrutinib.
| Strong control in CLL/SLL | In the ALPINE trial, a direct comparison against ibrutinib in relapsed or refractory CLL, zanubrutinib showed improved progression-free survival and a more favourable cardiac safety profile. The SEQUOIA trial supported its use in untreated CLL/SLL. |
| Benefit in Waldenstrom macroglobulinemia | In the ASPEN trial, a head-to-head study against ibrutinib, zanubrutinib showed at least comparable disease control with fewer cardiac and certain other side effects, supporting its use in WM. |
| Activity in mantle cell and marginal zone lymphoma | Trials in relapsed or refractory MCL and the MAGNOLIA study in MZL showed meaningful response rates, leading to accelerated approvals in these settings. |
| Added benefit in follicular lymphoma | The ROSEWOOD trial showed that adding zanubrutinib to obinutuzumab improved response rates and duration of response compared with obinutuzumab alone in relapsed or refractory FL. |
| A chemotherapy-free oral option | Zanubrutinib offers an oral, targeted treatment that can be taken at home and is generally manageable in the outpatient setting, with flexible once or twice daily dosing. |
Individual responses vary with disease type, genetic risk, prior treatment, age, and overall health. These reflect published clinical trial data.
Side effects of Zanubrutinib
Zanubrutinib is generally well tolerated for a cancer therapy, but side effects are common. Most are monitored and manageable, though some are serious and need urgent attention.
| Low blood counts | Low neutrophils, platelets, or red cells (anaemia) are common. Counts are monitored and the dose adjusted if needed. |
| Infections | Upper respiratory infections are frequent, and pneumonia or more serious infections can occur. Report fever or new symptoms promptly. |
| Bruising and bleeding | Easy bruising and minor bleeding are common; serious bleeding is less common but possible, so unusual bleeding should be reported. |
| Fatigue | Common and usually mild to moderate; it often improves over time. |
| Muscle or joint pain | Aches in muscles or joints can occur and are usually managed with supportive care. |
| Rash | Skin rash can develop; tell your team so it can be assessed and treated. |
| Diarrhoea | Common and usually manageable with diet and medication; report if severe or persistent. |
| High blood pressure | Blood pressure can rise during treatment and is monitored, with medication added if needed. |
| Heart rhythm problems | Atrial fibrillation or other arrhythmias can occur, though less often than with older BTK inhibitors. Report palpitations or an irregular heartbeat. |
| Second primary cancers | Including skin cancers. Use sun protection, check your skin, and attend recommended skin reviews. |
Contact your doctor immediately if you develop:
- Black or bloody stools, blood in urine, coughing up blood, or any unusual or heavy bleeding
- High fever, chills, severe weakness, or other signs of a serious infection
- A fast, pounding, or irregular heartbeat, fainting, or new chest pain
- Sudden severe headache, confusion, weakness on one side, or trouble speaking
- Severe or persistent shortness of breath, or severe ongoing diarrhoea
Safety precautions and key warnings
Tell your oncologist about your full medical history, all medicines and supplements, and any heart, bleeding, or infection problems before starting zanubrutinib.
- Tell your team about any history of bleeding problems, and review all blood thinners, aspirin, and anti-inflammatory drugs before starting
- Report any history of atrial fibrillation, irregular heartbeat, heart failure, heart disease, or high blood pressure
- Zanubrutinib is processed by the CYP3A liver enzyme, so strong CYP3A inhibitors or inducers may require a dose change
- Avoid St John's wort and tell your team about all supplements and herbal products, which can affect drug levels
- Tell your team about active infection, hepatitis B or C, or liver or kidney disease before treatment
- Your doctor may pause zanubrutinib before and after surgery or invasive procedures because of bleeding risk
- Pregnancy should be avoided; discuss reliable contraception and breastfeeding with your oncologist
- Use sun protection and attend skin checks, because second primary cancers including skin cancers can occur
Zanubrutinib combination and sequencing options
Zanubrutinib is used on its own in most B-cell cancers, but in some settings it is combined with other drugs, and there are clear next-line options if it stops working.
| Zanubrutinib alone (monotherapy) | The standard approach in CLL/SLL, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia in most approved settings. |
| Zanubrutinib + obinutuzumab (follicular lymphoma) | Approved in relapsed or refractory FL after two or more prior therapies, based on the ROSEWOOD trial, where the anti-CD20 antibody adds a second mechanism. |
| Zanubrutinib with anti-CD20 antibodies (trial settings) | Combinations with rituximab or obinutuzumab are studied in various B-cell cancers, chosen only by a specialist because side effects can increase. |
| Combinations with venetoclax (under study) | Fixed-duration BTK inhibitor plus BCL-2 inhibitor combinations are being explored in CLL to allow time-limited treatment, mainly in trials. |
| Switching or next-line therapy | If zanubrutinib stops working, options include venetoclax-based therapy, other targeted drugs, bispecific antibodies, CAR T-cell therapy for some lymphomas, or a clinical trial. |
If Zanubrutinib stops working
B-cell cancers can become resistant over time. Understanding why helps guide the next step.
| BTK and PLCG2 resistance mutations | Changes in the BTK protein or the related PLCG2 protein can reduce the drug's effect. Testing for these mutations is considered in selected cases at progression. |
| Disease transformation | Some lymphomas can transform into a more aggressive type. A repeat biopsy may be done if transformation is suspected, as this changes treatment. |
| Prior drug exposure | Outcomes depend on which classes you have already received, including prior BTK inhibitors, anti-CD20 antibodies, and chemoimmunotherapy, all of which are reviewed. |
| Re-testing at progression | Blood tests, flow cytometry, imaging, and bone marrow testing are repeated, and molecular or cytogenetic risk is reassessed before choosing next therapy. |
| Next-line options | These can include venetoclax-based treatment, anti-CD20 therapy, other targeted agents, bispecific antibodies, CAR T-cell therapy for selected lymphomas, or a clinical trial. |
Cost of Zanubrutinib by country
Zanubrutinib is a branded oral targeted drug without a generic version, so cost depends on the country, dose, treatment duration, insurance, and any patient-assistance programmes. Always ask for a full written estimate, including monitoring tests.
| India | Available at major cancer centres; cost depends on access route, duration, and supportive testing such as biopsy, flow cytometry, and scans. Hospital pharmacies and patient-support routes may help, so ask for a monthly estimate. |
| China | Developed and widely used in China, with NMPA approvals across several B-cell cancers including first-line CLL/SLL and WM. Pricing and access depend on hospital procurement and insurance category. CancerFax can help check practical access. |
| USA | High list price without insurance; most patients are covered through insurance, and manufacturer patient-assistance programmes may apply for eligible patients. |
| UK / Europe | Available through national health systems for approved indications, usually with minimal out-of-pocket cost for covered patients; self-pay costs are substantial. |
Availability of Zanubrutinib globally
Zanubrutinib is approved in more than 60 markets, though the exact approved indications and treatment lines vary by country and hospital.
India
Available for B-cell malignancies, with the exact indication and access route depending on registration and hospital procurement. CancerFax can help check access and second-opinion pathways.
China
A China-developed BTK inhibitor with broad NMPA approvals, including first-line CLL/SLL and Waldenstrom macroglobulinemia. CancerFax supports patients exploring treatment in Chinese oncology centres.
USA
FDA-approved across five B-cell cancer indications: CLL/SLL, Waldenstrom macroglobulinemia, relapsed MCL, relapsed MZL, and relapsed FL with obinutuzumab. The 160 mg tablet replaced the capsule in 2025.
Europe
Authorised in the European Union across several B-cell malignancies. Covered by national health systems for approved indications, with the tablet formulation under or following review.
Zanubrutinib in current clinical trials
Zanubrutinib is studied in more than 30 trials worldwide, including earlier-line use, fixed-duration combinations, and strategies for resistant disease.
| Fixed-duration combinations | Trials pairing zanubrutinib with venetoclax or anti-CD20 antibodies to allow time-limited, chemotherapy-free treatment, especially in CLL. |
| Earlier-line and frontline use | Studies extending zanubrutinib into earlier treatment lines and new disease settings across B-cell malignancies. |
| Overcoming BTK resistance | Research into next-generation and non-covalent BTK inhibitors, and sequencing strategies for disease that progresses on zanubrutinib. |
| Sequencing with newer therapies | Trials exploring how zanubrutinib fits alongside bispecific antibodies and CAR T-cell therapy in high-risk and relapsed disease. |
Your treatment journey with Zanubrutinib
Diagnosis and baseline testing
Risk assessment and treatment planning
Pre-treatment safety checks
Starting treatment
Monitoring and response assessment
Continuing, adjusting, or changing plan
Questions to ask your oncologist about Zanubrutinib
- Is Zanubrutinib appropriate for my exact type of B-cell cancer?
- Am I receiving it first-line or after relapse, and why?
- Will I take it alone or with another drug?
- Do I need molecular tests such as TP53, del(17p), MYD88, or CXCR4?
- Do I need heart rhythm or blood pressure monitoring?
- Should I stop it before surgery or dental work, and can I take blood thinners?
- What side effects should I report urgently?
- What are my options if Zanubrutinib stops working?
How CancerFax supports Zanubrutinib patients
CancerFax helps patients with B-cell cancers understand their reports, weigh their options, and access the right treatment.
| Report review | Upload your biopsy, flow cytometry, bone marrow, cytogenetics, and imaging reports, and our team reviews them and explains what they mean for zanubrutinib and other options. |
| Specialist connection | We connect patients with haematologists and lymphoma specialists experienced in BTK-inhibitor therapy in India, China, and other centres. |
| Second opinion | If you are unsure about your regimen, or the disease has relapsed, CancerFax arranges an expert second opinion to confirm the best path forward. |
| Access and cost navigation | We help check practical availability, formulation, and hospital options, and provide cost estimates where possible across India, China, and other countries. |
| Advanced therapy guidance | For patients who may need bispecific antibodies or CAR T-cell therapy after BTK inhibitors, CancerFax helps explore appropriate options and clinical trials. |
Frequently asked questions about Zanubrutinib
Common questions from patients and caregivers
Zanubrutinib is a targeted oral medicine, not chemotherapy. It blocks a protein called Bruton tyrosine kinase (BTK) that many B-cell cancers rely on to grow and survive. Because it targets a specific signalling pathway rather than broadly attacking all dividing cells, its side-effect pattern is different from standard chemotherapy. It is taken as a tablet at home and is used in several B-cell blood cancers.
Many patients begin to see improvement in blood counts, lymph node size, or symptoms within the first weeks to months, but the depth and timing of response vary by disease type. Your haematologist tracks response with blood tests, scans, and sometimes bone marrow testing. In some cancers, such as CLL, lymphocyte counts can briefly rise at the start before falling, which is expected and not a sign of failure.
Zanubrutinib was originally an 80 mg capsule, but a smaller 160 mg film-coated tablet replaced the capsule in the United States from October 2025, with the same approved uses and safety profile. The total recommended dose is 320 mg per day, which can be taken as two tablets once daily or split as twice-daily dosing. Which formulation and schedule you receive depends on what is registered and available in your country.
Zanubrutinib is processed by the liver through the CYP3A enzyme system, so medicines that strongly affect CYP3A can change its levels and your doctor may adjust the dose. Blood thinners, aspirin, and anti-inflammatory drugs can add to bleeding risk and should be reviewed. Tell your team about all prescriptions, supplements, and herbal products such as St John's wort before starting.
BTK inhibitors can affect heart rhythm and blood pressure, though zanubrutinib was designed to reduce some off-target effects seen with older drugs in this class. If you have a history of atrial fibrillation, palpitations, heart disease, or high blood pressure, your doctor may check your heart before and during treatment. Report any new palpitations, dizziness, fainting, or chest discomfort promptly.
Possibly. Because zanubrutinib can increase bleeding risk, your doctor may advise pausing it for a short period before and after planned surgery or invasive procedures, including some dental work. Never stop or restart on your own. Always tell any surgeon, dentist, or anaesthetist that you are taking zanubrutinib so they can plan safely.
If the cancer progresses, your haematologist will repeat blood tests, imaging, and sometimes a bone marrow test or biopsy, and may check for BTK or PLCG2 resistance mutations in selected cases. Options after zanubrutinib depend on the disease and prior treatment and can include venetoclax-based therapy, anti-CD20 antibodies, other targeted drugs, bispecific antibodies, CAR T-cell therapy for some lymphomas, or a clinical trial. A specialist second opinion can help identify the best next step.
Zanubrutinib is approved in more than 60 markets, including the USA, Europe, China, and India, though the exact approved indications and access route can differ by country and hospital. It is a China-developed BTK inhibitor and is widely used there, including for first-line CLL/SLL and Waldenstrom macroglobulinemia. CancerFax can help you check practical availability, hospital options, and second-opinion pathways across India, China, and other centres.